Trevi Therapeutics Presents Phase 2b CORAL Quality-of-Life Data for Haduvio Nalbuphine ER in IPF Chronic Cough at ERS Congress
Trevi Therapeutics (NASDAQ: TRVI) confirmed via its September 3, 2026 conference-participation announcement that Marlies Wijsenbeek MD PhD (Erasmus MC) will deliver an oral presentation on quality-of-life outcomes measured by the Leicester Cough Questionnaire (LCQ) from the Phase 2b CORAL trial of nalbuphine extended-release (Haduvio, an oral kappa-opioid agonist / mu-opioid antagonist) in idiopathic pulmonary fibrosis patients with chronic cough at the European Respiratory Society Congress in Barcelona. The 165-patient Phase 2b CORAL topline (reported June 2025) documented statistically significant reductions in 24-hour objective cough frequency across all Haduvio dose groups at week 6, with reductions seen at week 2 (the first time point measured). Trevi has completed the End-of-Phase 2 FDA meeting and continued Phase 3 initiation preparation through 2026. Chronic cough affects approximately 85% of IPF patients and has no FDA-approved treatment; the Merck-Bellus P2X3 antagonist gefapixant (Lyfnua) was approved for refractory chronic cough in adults in 2024 but was not developed for IPF-specific cough.